The following amendment has been made to the 'Results of General Meeting' announcement released on 21/09/2018 at 11:00 under RNS No 5577B.
Updated contact details.
All other details remain unchanged.
The full amended text is shown below.
("IXICO" or the "Company")
Result of General Meeting
IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, is pleased to announce that at the General Meeting held earlier today, the Resolutions to approve the Capital Reorganisation were duly passed.
Application has been made to AIM for the New Ordinary Shares to be admitted to trading on AIM. It is expected that such Admission will become effective and that dealings will commence in the New Ordinary Shares at 8.00 am on 24 September 2018.
Following Admission the Company's issued share capital will consist of 46,777,000 New Ordinary Shares of 1 pence each. The total number of voting rights in the Company will therefore be 46,777,000 New Ordinary Shares.
Unless otherwise stated, defined terms in this announcement not otherwise defined shall have the same meaning as is ascribed to them in the circular posted to shareholders on 3 September 2018.
For further information please contact:
Giulio Cerroni, Chief Executive Officer
Susan Lowther, Chief Financial Officer
Tel: +44 20 3763 7499
Shore Capital (Nomad and Broker)
Edward Mansfield / Anita Ghanekar / Daniel Bush
Tel: +44 20 7408 4090
FTI Consulting Limited (Investor Relations)
Simon Conway/Mo Noonan
Tel: +44 20 3727 1000
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our clients' neurodegenerative therapeutic pipeline through the application of novel medical imaging and mobile health digital technologies.
IXICO's specialist data analytics services are used by the global pharmaceutical industry to interpret brain scan data and digital biomarkers to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical trial process evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.